Yottar | $1,000,000 | (Aug 28, 2025)
EnsiliTech | $6,058,064 | (Aug 28, 2025)
Sequifi | $6,700,000 | (Aug 28, 2025)
Certified by Founder
Lodge
Illimis Therapeutics
start up
Korea, Republic Of
- Seoul
- 15/07/2025
- Series B
- $42,000,000
Illimis Therapeutics is a platform-based Korean biotech company developing a chimeric fusion protein platform for neurodegenerative diseases such as Alzheimer’s. Our platform is differentiated by its ability to address the concerns of antibody-induced neuroinflammation and subsequent ARIA (Amyloid-Related Imaging Abnormalities) often observed from existing antibody drugs that utilize FcR-mediated phagocytosis of microglia, by utilizing TAM receptor, a novel phagocytic receptor expressed on the surface of glial cells.
- Industry Biotechnology Research
- Website www.illimistx.com
- LinkedIn https://www.linkedin.com/company/illimis-therapeutics/
Bench IQ | $5,300,000 | (Aug 28, 2025)
Heave | $7,000,000 | (Aug 28, 2025)
Aurelian | $14,000,000 | (Aug 28, 2025)
InstaLILY AI | $25,000,000 | (Aug 28, 2025)
Matiks | $3,100,000 | (Aug 28, 2025)
Vox AI | $8,738,305 | (Aug 28, 2025)
Artificial Societies | $5,350,000 | (Aug 28, 2025)
Central | $8,600,000 | (Aug 28, 2025)
Aurasell AI | $30,000,000 | (Aug 27, 2025)